Predictors of treatment response to subthreshold micropulse laser and oral spironolactone therapy for central serous chorioretinopathy Authors: Sheng Gao, Yun Zhang, Ge Ge, Meixia Zhang Published: 2026 ABSTRACT AbstractObjectivesTo identify the specific predictors of treatment response to subthreshold micropulse laser (SML) and oral spironolactone therapy in patients with central serous chorioretinopathy (CSC).MethodsPatients diagnosed with CSC and treated with SML or spironolactone were included in this cohort study. Baseline characteristics, systemic factors, and various imaging characteristics were included as potential predictors of treatment response. Univariate and multivariate analysis was performed to identify predictive factors for the disease.ResultsA total of 103 eyes from 97 patients were included and divided into SML group (52 eyes) and spironolactone group (51 eyes). SRF resolution and OCT parameters, including CRT (p = 0.018) and SRF height (p < 0.001), decreased significantly in both groups, but SFCT decreased only in the spironolactone group. Regression analysis revealed that baseline SRF area was correlated with disease resolution in both SML (p = 0.005) and spironolactone (p = 0.016) groups, whereas changes in CRT and SFCT were correlated with a history of hyperuricemia (p = 0.047) and drinking (p = 0.035) only in the spironolactone group.ConclusionBoth SML and oral spironolactone are alternative therapies with similar efficacy. The SRF area at baseline can be a predictor of disease resolution. A history of hyperuricemia and drinking correlates with worse efficacy with spironolactone treatment.Trial registrationThe study was registered on Chinese Clinical Trial Registry (identifier: ChiCTR2100044356) at 17 March 2021.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12886-026-04956-w.Keywords: Central serous chorioretinopathy, Subthreshold micropulse laser, Spironolactone, Specific predictors, Treatment response Introduction Central serous chorioretinopathy (CSC) is characterized by neurosensory detachment with subretinal fluid (SRF) with or without pigment epithelial detachment (PED), usually associated with retinal pigment epithelium (RPE) dysfunction, choroidal thickening, hyperpermeability and venous overload. The disease affects mainly young to middle-aged men; although most cases can resolve spontaneously within 6 months, some patients progress to the chronic phase and have persistent SRF and visual impairment [1]. Photodynamic therapy (PDT), subthreshold micropulse laser (SML) therapy, and oral mineralocorticoid receptor antagonist (MRA) have been reported as options for treating CSCs. Since the wide variety of disease presentations and clinical courses and the current lack of consensus regarding therapy, controversy regarding the treatment of CSC remains [2]. Increasing evidence in recent years supports the use of half-dose PDT as the preferred therapeutic option for chronic CSC, but this approach is limited by the shortage of verteporfin. Other common alternative treatments in China include SML and oral MRA, but compelling evidence supporting the efficacy of SML and oral MRA is currently lacking, and therapeutic options should be evaluated on a case-by-case basis [3]. Previous studies have reported multiple factors that may be helpful for predicting the course and outcomes of CSC, such as the age of disease onset, incidence of macular complications, choroidal thickness, vascularity index, and presence of an intact ellipsoid zone [4]. However, based on differences in the mechanism of SML and oral MRA, there may be specific predictive factors corresponding to different therapies. To our knowledge, no study has reported comparison criteria. These would be of clinical importance as possibly different benefit identifications for CSC patients from SML or oral MRA therapies. The aim of this study was to evaluate CSC patients treated with SML therapy or oral spironolactone to identify possibly specific predictive factors corresponding to treatment response. Materials and methods Study design This prospective cohort study was conducted at West China Hospital, Sichuan University, China. Data were collected from a consecutive series of patients treated with SML therapy or oral spironolactone therapy for CSC between August 2020 and January 2022. The study adhered to the principles of the Declaration of Helsinki and was approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (identifier: 20201187) and registered on ChiCTR (identifier: ChiCTR2100044356). Informed consent was obtained from all participants before treatment. Study patients Patients with chronic CSC with a minimum of 6 months of follow-up were included in the study. Chronic CSC was defined as persistent SRF lasting for more than 3 months after conservative management. The diagnosis of CSCR was confirmed using optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). All study patients were administered SML therapy or oral spironolactone therapy. Eligible patients were assigned to two groups based on the month of their first presentation rather than baseline OCT morphological phenotypes, with patients presenting in odd-numbered months receiving SML and those presenting in even-numbered months receiving oral spironolactone. The exclusion criteria were the presence of any other retinal disease, such as choroidal neovascularization; any history of CSC treatment in the year before inclusion; a follow-up period of less than 6 months; and insufficient image quality. Data collection Data collected included age, sex, ocular history, medication, smoking status, drinking status, systemic steroid use, hypertension status, diabetes status, hyperuricaemia status, hyperlipidaemia status, and family history. Disease features included disease duration, CSC classification, and single or double eyes. All patients underwent comprehensive ocular examination, including slit lamp examination, indirect ophthalmoscopy, best corrected visual acuity (BCVA), OCT, OCTA and FFA examination. Depending on response categories, we divided patients according to treatment efficacy into two groups: the response group (complete resolution of SRF after treatment) and the nonresponse group (partial or no resolution of SRF after treatment), which was defined as the primary outcome. Treatments A 577 nm yellow laser system (EasyRet, Quantel Medical, Cedex, France) was used in micropulse mode with standardized SML treatment parameters for all patients. Oral spironolactone treatment: The patients in the spironolactone group started spironolactone 20 mg/tid after meals until the SRF dissolved. The dose was decreased or discontinued at the discretion of the physician according to the patient’s condition. Multimodal imaging FFA (Heidelberg Engineering) was performed for each patient at baseline before treatment. Routine retinal imaging, which included six radial scans centred on the fovea with OCT (Heidelberg Engineering), was performed at each follow-up visit. Quantitative OCT measurements included central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), the height and area of the SRF on B-scans, and the longest diameter of the SRF measured from the longest B-scan section of the SRF. The latter three measurements form the components of the SRF baseline parameters. All OCT measurements were independently performed by two examiners with proprietary software available on OCT machines. Qualitative OCT parameters included SRF features (focal bump, diffuse bump, focal flat, diffuse flat); presence or absence of EZ-IZ disruption, retinal dimple sign and macular PED; PED features (dome shaped, irregular flat); presence or absence of RPE local bump and ellipsoid zone thickening; and presence or absence of RPE alteration of contralateral eyes. Pattern (atypical, smokestack, ink blot), location (extrafovea, parafovea, fovea), and number (single, multiple) of leakages, as determined by FFA, were recorded. OCTA was performed using a Zeiss prototype (Cirrus HD-OCT 5000, Carl Zeiss Meditec) to exclude potential CNV at baseline. All image measurements were performed by two independent experienced observers who were masked to treatment allocation. Any discrepancies were resolved by consensus. Statistical analysis All data were evaluated using SPSS 26.0 (SPSS, Inc., Chicago, IL, USA) for statistical analysis. All variables were checked for normality with the Shapiro–Wilk test. Differences between groups were tested by Student’s t test or the Mann‒Whitney U test for continuous variables and Pearson’s chi-square test for categorical variables. Univariate and multivariate analyses were used to identify risk factors associated with treatment response. The categorical outcome measure (responder categories) adopted a logistic regression model and the continuous outcome measure (SRF height, etc.) adopted a linear regression model to identify risk factors. Only risk factors with a P value < 0.05 were considered for the multivariate regression analysis. P values < 0.05 were considered to indicate statistical significance. Results Baseline characteristics The study included 103 eyes of 97 patients: 50 patients (52 eyes) in the SML group and 47 patients (51 eyes) in the spironolactone group. The mean age of all the CSC patients was 46.37 ± 9.10 years, and the study population comprised 77 males (79.4%) and 20 females (20.6%). The baseline systemic factors and disease characteristics are detailed in Table 1. There were no significant differences in baseline systemic factors or disease characteristics between the SML and spironolactone groups. Table 1Patient demographics, baseline characteristics and image featuresTotal (n = 97,103 eyes)SML group (n = 50, 52 eyes)Spironolactone group (n = 47, 51 eyes)c2/t P Systemic factors Age (yrs)46.37 ± 9.1046.02 ± 9.4846.74 ± 8.760.390.697 Gender (male, n%)77 (79.4%)41 (82.0%)36 (76.6%)0.430.511 Smoke38 (39.2%)20 (40.0%)18 (38.3%)0.360.835 Drinking41 (42.2%)21 (42.0%)19 (40.4%)2.540.352 Systemic steroid2 (2.1%)2 (4.0%)0 (0%)-0.495 Hypertension6 (6.2%)4 (8.0%)2 (4.3%)-0.678 Diabetes7 (7.2%)4 (8.0%)3 (6.4%)-1.000 Hyperuricemia6 (6.2%)3 (6.0%)3 (6.4%)-1.000 Hyperlipidemia9 (9.3%)6 (12.0%)3 (6.4%)-0.488 Family history1 (1.0%)1 (2.0%)0 (0%)-1.000 Disease characteristics Duration (M)13.82 ± 23.7214.31 ± 25.8013.29 ± 21.560.210.832 CSC eye (single, n%)63 (64.9%)32 (64.0%)32 (64.0%)-0.840 CSC classification (chronic, n%)84 (81.6%)43 (82.7%)41 (80.4%)-0.763 Baseline characteristics BCVA (logMAR)0.37 ± 0.380.35 ± 0.380.39 ± 0.370.5250.601 SRF Height (µm)171.11 ± 107.00178.25 ± 101.90163.82 ± 112.510.6820.497 Longest diameter (µm)2733.34 ± 1370.352937.25 ± 1413.152525.43 ± 1306.351.5350.128 Area (mm2)0.27 ± 0.270.30 ± 0.260.25 ± 0.271.0070.316 CRT (µm)349.57 ± 128.67354.73 ± 126.36344.31 ± 132.040.4090.683 SFCT (µm)445.17 ± 114.32442.96 ± 107.15447.41 ± 122.220.1970.845 Image features SRF feature10.370.016* Focal bump33 (32.0%)10 (19.2%)23 (45.1%) Diffuse bump25 (24.3%)12 (23.1%)13 (25.5%) Focal flat34 (33.0%)22 (42.3%)12 (23.5%) Diffuse flat11 (10.7%)8 (15.4%)3 (5.9%) EZ-IZ disruption72 (69.9%)36 (69.2%)36 (70.6%)0.020.881 Retinal dimple sign11 (10.7%)9 (17.3%)2 (3.9%)4.840.028* Macular PED44 (42.7%)21 (40.4%)23 (45.1%)0.230.629 PED feature0.110.741 Dome shaped20 (45.4%)9 (42.9%)11 (47.8%) Irregular flat24 (54.5%)12 (57.1%)12 (52.2%) RPE local bump77 (74.8%)40 (76.9%)37 (72.5%)0.260.609 Ellipsoid zone thickening75 (72.8%)36 (69.2%)39 (76.5%)0.680.409 RPE alteration of contralateral eyes45 (50.0%)24 (51.1%)21 (48.8%)0.050.833 Leakage pattern3.890.143 Atypical50 (50.5%)22 (42.3%)30 (58.8%) Smokestack11 (10.7%)8 (15.4%)3 (5.9%) Ink blot40 (38.8%)22 (42.3%)18 (35.3%) Leakage location3.120.194 Extrafovea47 (45.6%)26 (50.0%)21 (41.2%) Parafovea51 (49.5%)22 (42.3%)29 (56.9%) Fovea5 (4.9%)4 (7.7%)1 (2.0%) Leakage number0.150.702 Single75 (72.8%)37 (71.2%)38 (74.5%) Multiple28 (27.2%)15 (28.8%)13 (25.5%)SML, subthreshold micropulse laser; CSC, central serous chorioretinopathy; BCVA, best-corrected visual acuity; SRF, subretinal fluid; CRT, central retinal thickness; SFCT: subfoveal choroidal thickness; PED: pigmental epithelial detachment; RPE: retinal pigmental epithelium Patient demographics, baseline characteristics and image features SML, subthreshold micropulse laser; CSC, central serous chorioretinopathy; BCVA, best-corrected visual acuity; SRF, subretinal fluid; CRT, central retinal thickness; SFCT: subfoveal choroidal thickness; PED: pigmental epithelial detachment; RPE: retinal pigmental epithelium The baseline BCVA and image characteristics of the two groups are summarized in Table 1. There were no apparent differences between the groups in SRF, CRT, or SFCT at baseline. According to the SRF features (see Figure, Supplemental Digital Content 1, which showed different SRF feature), the SRF was divided into focal bump, diffuse bump, focal flat, diffuse flat. The other qualitative features of the OCT images are shown in Fig. 1, including EZ-IZ disruption, retinal dimple sign, dome-shaped PEDs, irregular flat PEDs, RPE local bump, ellipsoid zone thickening, and RPE alteration of contralateral eyes. The different patterns, locations, and numbers of leakages on FFA are presented in Supplemental Digital Content 2 (see Figure, Supplemental Digital Content 2, which showed different leakage patterns). The leakage patterns were divided into atypical, smokestack, and ink blot leakage. Leakage location was assured based on the distance from the fovea (extrafovea, parafovea and fovea). Single or multiple leakage points were also recorded from the FFA images. Except for the SRF features and retinal dimple sign, there was no significant difference in image features between the two groups. The different features of OCT images in CSC patients. (A) EZ-IZ disruption (white arrows). (B) Retinal dimple sign (asterisk). (C) Dome-shaped PED (white box). (D) Irregular flat PED (white box). (E) Irregular flat PED (white box) without ellipsoid zone thickening (white arrow). (F) Irregular flat PED (white box) with ellipsoid zone thickening (white arrow). (G) RPE local bump (white box). (H) RPE local bump (white box) and EZ-IZ disruption (white arrows) Treatment responses The rate of complete SRF resolution in the SML group was 61.5% (32 eyes), while it was 45.1% (23 eyes) in the spironolactone group, without significant differences (p = 0.341). Only 8 patients in the SML group and 11 patients in the spironolactone group had an SRF reduction of less than 50% after treatment. The resolving times of SRF were 1.54 ± 0.96 and 1.39 ± 1.16 months in the SML group and spironolactone group (p = 0.635), respectively. There was no significant improvement in BCVA in either the SML group (logMAR 0.36 ± 0.50) or the spironolactone group (logMAR 0.36 ± 0.41) at 6 months. Conversely, OCT parameters, including SRF height (p < 0.001) and CRT (p = 0.018), significantly improved through the visit period. The mean SRF height decreased to 56.63 ± 79.63 μm in the SML group and to 82.46 ± 84.63 μm in the spironolactone group at 6 months. CRT decreased throughout the entire period (final to 229.54 ± 101.45 μm in the SML group and 259.86 ± 96.58 μm in the spironolactone group). SFCT in both groups was greater at baseline and decreased significantly only in the spironolactone group (final 398.55 ± 119.24 μm), but not in the SML group (final 462.16 ± 107.74 μm). Predictive factors Univariate logistic regression analysis was used to identify the factors correlated with response category (response, nonresponse). Only the RPE local bump was associated with the response category in the SML group (Exp(β) = 0.106, P = 0.042) (see Table, Supplemental Digital Content 3, which showed the results of univariate logistic regression analysis of the risk of complete SRF resolution). Univariate linear regression analysis for risk predictors was performed for the change in SRF height (see Table, Supplemental Digital Content 4, which represented the results of univariate linear regression analysis of the risk of SRF height), the change in CRT (see Table, Supplemental Digital Content 5, which showed the results of univariate linear regression analysis of the risk of CRT), and the change in SFCT (see Table, Supplemental Digital Content 6, which demonstrated the results of univariate linear regression analysis of the risk of SFCT), respectively. In the SML group, hyperuricaemia, CSC classification, CRT, baseline SRF parameters, and qualitative OCT features (PED feature, RPE local bump, ellipsoid zone thickening) might be factors correlated with changes in anatomical variables (SRF height, CRT, and SFCT). In the spironolactone group, systemic factors (hyperuricaemia and drinking), CSC classification, CRT, baseline parameters of SRF, SRF features and EZ-IZ disruption could be factors correlated with changes in anatomical variables (SRF height, CRT, and SFCT). Multivariate analysis was performed for these results, which included all variables with a P value < 0.05 in the univariate analysis. After stepwise linear regression analysis, the final model for the change in SRF height was significant and revealed to be an independent factor for less SRF height reduction a larger baseline SRF area in both the SML (p = 0.005) and spironolactone (p = 0.016) groups (Table 2). Table 2Results of multiple linear regression analysis of the association between changes in SRF height and baseline predictorsVariableSML groupSpironolactone groupβ [95%CI] P β [95%CI] P Hyperuricemia-59.134 [-194.658, 76.391]0.379--Leakage location32.131 [-19.247, 83.508]0.211--SRF longest diameter0.031 [-0.009, 0.071]0.1220.002 [-0.031, 0.036]0.891SRF area-345.792 [-580.811, -110.772] 0.005 * -299.514 [-539.550, -59.477] 0.016 * CRT-0.266 [-0.585, 0.054]0.100-0.387 [-0.908, 0.134]0.140CSC classification--33.504 [-61.112, 128.121]0.476SRF feature--25.572 [-28.136, 79.280]0.339* P<0.05 indicates a statistically significant differenceSML, subthreshold micropulse laser; SRF, subretinal fluid; CRT, central retinal thickness; CSC: central serous chorioretinopathy Results of multiple linear regression analysis of the association between changes in SRF height and baseline predictors * P<0.05 indicates a statistically significant difference SML, subthreshold micropulse laser; SRF, subretinal fluid; CRT, central retinal thickness; CSC: central serous chorioretinopathy In terms of CRT change, a stepwise linear regression led to a final significant model only in the spironolactone group, identifying hyperuricaemia history as the independent factor (p = 0.047) (Table 3). Considering the change in SFCT, only drinking history was identified as a significant predictor in the spironolactone group (p = 0.035) (Table 4). In essence, CSC patients with a history of hyperuricemia and drinking showed worse recovery from CRT and SFCT when treated with spironolactone. Table 3Results of multiple linear regression analysis of the association between CRT change and baseline predictorsVariableSML groupSpironolactone groupβ [95%CI] P β [95%CI] P CSC classification21.851 [-63.453, 107.154]0.604--Leakage location25.847 [-37.216, 88.909]0.408--SRF height-0.574 [-1.390, 0.242]0.161-0.708 [-1.753, 0.336]0.176SRF longest diameter0.020 [-0.035, 0.074]0.4650.006 [-0.033, 0.045]0.744SRF area-224.310 [-635.989, 187.368]0.274-224.927 [-634.839, 184.985]0.271Hyperuricemia---140.478 [-279.256, -1.699] 0.047 * SRF feature--40.387 [-28.850, 109.624]0.243EZ-IZ disruption--51.309 [-46.299, 148.917]0.292* P < 0.05 indicates a statistically significant differenceSML, subthreshold micropulse laser; CSC: central serous chorioretinopathy; SRF, subretinal fluid Results of multiple linear regression analysis of the association between CRT change and baseline predictors * P < 0.05 indicates a statistically significant difference SML, subthreshold micropulse laser; CSC: central serous chorioretinopathy; SRF, subretinal fluid Table 4Results of multiple linear regression analysis of the association between SFCT change and baseline predictorsVariableSML groupSpironolactone groupβ [95%CI] P β [95%CI] P PED feature51.470 [-31.541, 134.480]0.203--RPE local bump38.242 [-54.414, 130.898]0.389--Ellipsoid zone thickening-30.864 [-113.874, 52.147]0.436--Drinking---34.828 [-67.081, -2.576] 0.035 * SRF area---67.788 [-172.390, 36.815]0.196CRT--0.071 [-0.208, 0.351]0.606* P < 0.05 indicates a statistically significant differenceSML, subthreshold micropulse laser; PED: pigmental epithelial detachment; RPE: retinal pigmental epithelium; SRF, subretinal fluid; CRT, central retinal thickness Results of multiple linear regression analysis of the association between SFCT change and baseline predictors * P < 0.05 indicates a statistically significant difference SML, subthreshold micropulse laser; PED: pigmental epithelial detachment; RPE: retinal pigmental epithelium; SRF, subretinal fluid; CRT, central retinal thickness Discussion CSC is a relatively common and self-limited fundus disease, but persistent macular SRF leakage causes permanent vision loss due to photoreceptor cell damage and diffuse RPE disruption [1]. The lack of validated therapeutic evidence has complicated studies regarding the natural disease course, spontaneous resolution and disease subtypes, with different treatment responses occurring even under the same treatment due to individual differences, all of which are important for identifying beneficial prognostic parameters in interventional trials [5]. This investigation of a cohort of patients with CSC and their treatment responses to SML or oral spironolactone revealed different responses in terms of SRF resolution and retinal structures and allowed for the identification of specific predictive factors. We studied the predictive factors of SRF resolution and anatomical structure in CSC patients. The baseline SRF area appeared to be positively correlated with SRF resolution both during SML and spironolactone treatment, whereas changes in CRT and SFCT were correlated with a history of hyperuricaemia and drinking only in the spironolactone group. Our results differ from previous findings reporting predictive factors for treatment efficacy. Meltem et al. reported that the presence of intact baseline EZ and RPE and extrafoveal foci could be used as predictors of SML treatment success in chronic CSC patients [6]. Furthermore, lower SRF, narrower PED, and fewer hyperreflective foci, as well as baseline SFCT and RPE/inner choroid alterations, were proposed to predict a good response to SML [7, 8]. For spironolactone treatment, Borrelli et al. suggested that OCT parameters at baseline, including thicker SFCT, smaller maximum diameter of SRF, less PED and fewer intraretinal hyperreflective foci, were independently significant predictors of SRF resolution [9]. However, Bousquet and Gergely et al. reported that baseline SFCT was the only factor associated with treatment response [10, 11]. However, our correlation analyses revealed that it did not seem possible to predict the outcome of SRF resolution from a morphological point of view under both SML and spironolactone treatment. The correlation of the changes in SRF height appears to be related to the baseline SRF area, but not to other characteristics of OCT or FFA. The findings of Subhi’s recent study were partly consistent with our results, and they reported that the baseline characteristics of SRF were unable to predict the outcomes after either SML or half-dose PDT treatment [12]. These results suggested that the residual height of the SRF after treatment with SML or spironolactone may be correlated only with baseline SRF area. For patients with a history of hyperuricaemia or drinking, SML therapy was recommended rather than oral spironolactone. Overall, nearly half of the entire cohort achieved complete SRF resolution after treatment. In terms of the anatomic structure, both the SRF height and CRT significantly improved. SFCT decreased markedly only in patients treated with oral spironolactone. This may be due to systemic spironolactone administration blocking the abnormally activated mineralocorticoid receptor pathway, which plays an important role in the pathogenesis of CSC, thereby reducing intravascular hydrostatic pressure and vascular permeability in the choroid and improving abnormally dilated choroidal vessels [13, 14]. In addition to spironolactone, other mineralocorticoid receptor antagonists have also shown promising effects in chronic CSC. A pilot study demonstrated that continuous eplerenone treatment may provide sustained benefits even after 4 years in exudative chronic CSC [15]. Therefore, the therapeutic potential of mineralocorticoid receptor antagonism in chronic CSC involves not only spironolactone but also other agents in the same class, supporting a unifying biological mechanism underlying the resolution of subretinal fluid. These findings highlight the importance of mineralocorticoid pathway modulation in the management of chronic CSC. However, there were limited satisfactory visual functional outcomes in both the SML and spironolactone groups because long-lasting SRF can lead to irreversible damage to the RPE and neuroretina [16]. Currently, most studies have reported the efficacy of SML and MRA in the treatment of CSC, which is consistent with our results [17]. In contrast to other studies, we did not analyse the factors correlated with the changes in BCVA because there was no significant improvement in visual prognosis in the two groups [18]. We speculated that CSC patients who had a wider range of SRF at baseline may present a wider range of RPE decompensation and more difficulty recovering normal RPE function. We observed EZ-IZ disruption in 72 eyes (69.9%) in the entire cohort, which, as an OCT-based sign, is commonly associated with a poor visual prognosis, as previously reported [19]. Macular PED was identified in 44 eyes (42.7%) and there was no difference between the two groups. A local RPE bump was observed in the RPE layer in 77 eyes (74.8%), which was previously described by Montero and Hyung et al. [20, 21]. They suggested that these lesions were related to angiographic leakage sites and might indicate minimal PED or PED with sub-pigmental epithelial exudates. In particular, our results revealed the correlation between complete SRF regression and local RPE bumps in patients with CSC who receive SML treatment. We speculated that RPE dysfunction potentially caused local bump formation in the RPE, which might represent a preclinical or subclinical state of the disease. SML treatment might focus on local bumps in the RPE specifically and stimulate RPE cells to improve pump function and discharge residual fluid [22]. Recent study demonstrated significant structural remodeling of the Sattler–Bruch layer complex after SML in chronic CSC, suggesting that the therapeutic effect of SML may involve not only RPE activation but also direct modulation of choroidal microvascular function [23]. Additionally, ellipsoid zone thickening was found in 75 eyes (72.8%). Approximately 43.7% of patients (45 eyes) with CSC had alterations in the RPE of the contralateral eye in the whole cohort. Notably, we strictly excluded potential CNV at baseline using OCTA to avoid the potential influence on SML and spironolactone treatment. We found that a history of hyperuricaemia and alcohol consumption were poor predictors of treatment response to oral spironolactone treatment in chronic CSC patients, which has not been reported in previous studies. Alcohol could play a direct role in the pathogenesis of CSC by disrupting nitric oxide-mediated vasomotor function [24]. Hyperuricaemia is also associated with alcohol intake [25]. In addition, long-term alcohol intake and hyperuricaemia are related to poor lifestyle habits and chronic psychological stress [26]. Chronic stress increases the risk of alcohol intake, which elevates the levels of catecholamines and glucocorticoids and, conversely, forms a vicious cycle [27]. Therefore, we speculate that spironolactone treatment may be ineffective in CSC patients who have a history of hyperuricemia and drinking due to its complex pathogenesis and severe chronic stressors. This hypothesis is novel but speculative. It should be noted that alcohol intake and hyperuricemia were analysed as binary variables for exploratory purposes. These systemic factors represent complex and heterogeneous exposures, and the simplified assessment together with the relatively small subgroup size limits definitive conclusions. Therefore, the findings related to systemic factors should be considered hypothesis-generating rather than conclusive, which still needs for validation in larger cohorts. The study had certain limitations. This was an exploratory study with a limited number of eyes and a limited follow-up period. Treatment allocation was based on the month of presentation rather than baseline OCT phenotypes. Potential imbalance in baseline morphological characteristics between groups may have introduced slight bias. Second, because this was an exploratory morphological study, we cannot exclude the possibility that a study with a larger sample would be able to identify a significant predictive ability of treatment response based on the measured morphology characteristics of the SRF. Also, heterogeneity and natural disease course were perhaps involved reasons, which differed from previous literatures emphasized other OCT biomarkers. Third, we described SRF morphology based on three parameters and qualitative retinal morphological outcomes to extrapolate our understanding of treatment response, which was also a limitation. Thus, we could only speculate on the predictability of the outcomes we investigated but could not fully exclude the possibility that other potential SRF or retinal morphological parameters were not considered in our study. Finally, in this study, variables were screened by univariate analysis (p < 0.05) into multiple regression models, without statistical correction for multiple comparisons, which may increase the risk of type 1 errors. Therefore, the conclusions of the study need to be verified by more rigorous design in the future. In conclusion, the SRF area at baseline correlates with the treatment response in both SML therapy and spironolactone therapy but cannot predict visual outcomes. The predictors of treatment response to oral spironolactone therapy also include systemic factors (history of hyperuricaemia or drinking). A detailed understanding of these parameters can aid in planning therapeutic interventions and predicting treatment response in eyes with long-term CSC. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements None. Author contributions Meixia Zhang, Sheng Gao, Yun Zhang, and Ge Ge contributed to the conception and design of the study. Material preparation, data collection, and analysis were performed by Sheng Gao and Ge Ge. The first draft of the manuscript was written by Sheng Gao. Sheng Gao, Yun Zhang, and Meixia Zhang commented on the manuscript. All authors reviewed and approved the final manuscript. Funding This study was funded by the Sichuan Provincial Science and Technology Support Project, grant numbers 2025ZNSFSC0698 and 2024YFFK0303. Data availability All data included in the statistical analysis are available upon request from the corresponding author. Declarations Ethics approval and consent to participate This study was registered on ChiCTR (identifier: ChiCTR2100044356). The study adhered to the principles of the Declaration of Helsinki and was approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (identifier: 20201187). All patients signed an informed consent form. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data included in the statistical analysis are available upon request from the corresponding author.